{"analyses":[{"groupDescription":"Compare the rate of confirmed PR or better between treatment arms.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1130","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"14"}]}],"title":"Very Good Partial Response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Unconfirmed Partial Response (uPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"Per International Uniform Response Criteria for Multiple Myeloma PR- ≥ 50% reduction in size of soft tissue plasmacytomas \\& plasma cells; ≥ 50% decrease in serum \\& reduction in urine M protein ≥ 90% or to \\< 200 mg/24hr or ≥ 50% decrease in difference in uninvolved \\& involved serum free light chain levels; VGPR- PR + Serum and urine M proteins detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M protein \\& urine M protein \\< 100 mg/24 hrs; uPR- 1 objective status of PR, but confirmation studies are not done, or do not meet the requirements necessary to confirm response; SD- does not meet criteria for sCR, CR, VGPR, PR or PROG; PROG- new or increase in size of existing bone lesions or soft tissue plasmacytomas/ development of hypercalcemia attributable solely to MM/ ≥ 25% increase from baseline/ lowest response level of either serum or Urine M protein, difference in involved \\& uninvolved serum free light chain level or bone marrow plasma cell percentage.","groups":[{"description":"Patients receive 20 mg dexamethasone IV and low-dose (27 mg/m\\^2) carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m\\^2.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Arm I (Dexamethasone, Low-dose Carfilzomib)"},{"description":"Patients receive 20 mg dexamethasone IV and high-dose (56 mg/m\\^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m\\^2 over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Arm II (Dexamethasone, High-dose Carfilzomib)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This population includes eligible and analyzable patients who had a follow-up response assessment.","reportingStatus":"POSTED","timeFrame":"From date of registration to date of best response while on study treatment","title":"Best Overall Response - Partial Response (PR), Very Good Partial Response (VGPR), Unconfirmed PR (uPR), Stable Disease (SD) Progression (PROG)","type":"SECONDARY","unitOfMeasure":"Participants"}